PMID- 12517263
OWN - NLM
STAT- MEDLINE
DCOM- 20031219
LR  - 20191025
IS  - 1471-2598 (Print)
IS  - 1471-2598 (Linking)
VI  - 2
IP  - 8
DP  - 2002 Dec
TI  - Genetically modified dendritic cells--a new, promising cancer treatment strategy?
PG  - 835-45
AB  - Dendritic cells (DCs), the most potent antigen-presenting cells (APCs), were 
      discovered almost 30 years ago. Due to the priming of antigen-specific immune 
      responses mediated by CD4+ and CD8+ lymphocytes, DCs are crucial for the 
      induction of adaptive immunity against cancer. Therefore, vaccination of cancer 
      patients with DCs presenting tumour-associated antigens (TAAs) have been believed 
      to be a promising anticancer strategy. Multiple clinical trials have been carried 
      out in order to evaluate the safety and efficacy of cancer vaccines based on 
      antigen-pulsed DCs. However, pulsing of DCs with particular peptides has several 
      disadvantages: i) short-time duration of antigen-major histocompatability complex 
      (MHC) complexes, ii) a requirement for matching defined peptides with MHC 
      complexes and iii) exclusive presentation of single antigen epitopes. Application 
      of gene transfer technologies in the field of DC-based vaccines made possible the 
      development of novel, anticancer immunisation strategies. In several animal 
      models, DCs modified with genes encoding TAA or immunostimulatory proteins have 
      been shown to be effective in the induction of antitumour immune responses. Based 
      on these encouraging results, a first clinical trial of prostate cancer patients 
      vaccinated with gene modified DCs has recently been initiated. In this article, 
      methods used for genetic modification of DCs and anticancer vaccination 
      strategies based on genetically modified DCs are reviewed.
FAU - Wysocki, P J
AU  - Wysocki PJ
AD  - Department of Cancer Immunology, University School of Medical Sciences at 
      GreatPoland Cancer Centre, Poznan, Poland. pwysocki@plusnet.pl
FAU - Grabarczyk, P
AU  - Grabarczyk P
FAU - Mackiewicz-Wysocka, M
AU  - Mackiewicz-Wysocka M
FAU - Kowalczyk, D W
AU  - Kowalczyk DW
FAU - Mackiewicz, A
AU  - Mackiewicz A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
SB  - IM
MH  - Animals
MH  - Dendritic Cells/*physiology/*transplantation
MH  - Genetic Therapy
MH  - Humans
MH  - Neoplasms/*therapy
RF  - 109
EDAT- 2003/01/09 04:00
MHDA- 2003/12/20 05:00
CRDT- 2003/01/09 04:00
PHST- 2003/01/09 04:00 [pubmed]
PHST- 2003/12/20 05:00 [medline]
PHST- 2003/01/09 04:00 [entrez]
AID - 10.1517/14712598.2.8.835 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2002 Dec;2(8):835-45. doi: 10.1517/14712598.2.8.835.